PMID- 7890239
OWN - NLM
STAT- MEDLINE
DCOM- 19950418
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 36
IP  - 1
DP  - 1995 Jan
TI  - Photosensitisation and photodynamic therapy of oesophageal, duodenal, and 
      colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a 
      pilot study.
PG  - 67-75
AB  - The first study of photodynamic therapy in the human gastrointestinal tract using 
      5 aminolaevulinic acid (ALA) induced protoporphyrin IX as the photosensitising 
      agent is described. Eighteen patients with colorectal, duodenal, and oesophageal 
      tumours were studied. After 30-60 mg/kg of ALA given orally, biopsy specimens of 
      tumour and adjacent normal mucosa were taken 1-72 hours later. These specimens 
      were examined by quantitative fluorescence microscopy for assessment of 
      sensitisation with protoporphyrin IX. Ten patients were given a second dose of 
      ALA a few weeks later and their tumours were treated with red laser light (628 
      nm). With 30 mg/kg ALA, the highest fluorescence values were detected in the 
      duodenum and oesophagus, and the lowest in the large bowel. Doubling the ALA dose 
      in patients with colorectal tumours gave protoporphyrin IX fluorescence 
      intensities similar to those in patients with upper gastrointestinal lesions and 
      improved the tumour:normal mucosa protoporphyrin IX sensitisation ratio. The 
      treated patients showed superficial mucosal necrosis in the areas exposed to 
      laser light. Six patients had transient rises in serum aspartate 
      aminotransferases, two mild skin photosensitivity reactions, and five mild nausea 
      and vomiting. In conclusion, photodynamic therapy with systemically administered 
      ALA may be a promising technique for the treatment of small tumours and areas of 
      dysplasia such as in Barrett's oesophagus.
FAU - Regula, J
AU  - Regula J
AD  - National Medical Laser Centre, Department of Surgery, University College London 
      Medical School.
FAU - MacRobert, A J
AU  - MacRobert AJ
FAU - Gorchein, A
AU  - Gorchein A
FAU - Buonaccorsi, G A
AU  - Buonaccorsi GA
FAU - Thorpe, S M
AU  - Thorpe SM
FAU - Spencer, G M
AU  - Spencer GM
FAU - Hatfield, A R
AU  - Hatfield AR
FAU - Bown, S G
AU  - Bown SG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Prodrugs)
RN  - 0 (Protoporphyrins)
RN  - 7412-77-3 (protoporphyrinogen)
RN  - 88755TAZ87 (Aminolevulinic Acid)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aminolevulinic Acid/adverse effects/blood/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Duodenal Neoplasms/*drug therapy
MH  - Esophageal Neoplasms/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Microscopy, Fluorescence
MH  - Middle Aged
MH  - Photochemotherapy/adverse effects/*methods
MH  - Pilot Projects
MH  - Prodrugs/*therapeutic use
MH  - Protoporphyrins/*biosynthesis
PMC - PMC1382355
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
PMCR- 1995/01/01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PHST- 1995/01/01 00:00 [pmc-release]
AID - 10.1136/gut.36.1.67 [doi]
PST - ppublish
SO  - Gut. 1995 Jan;36(1):67-75. doi: 10.1136/gut.36.1.67.